OverviewSuggest Edit

Valbiotis is a company that develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. The Company's “Nutrition Healthcare” approach seeks to develop tools designed to prevent type 2 diabetes, NASH (non-alcoholic steatohepatitis) and obesity. Valbiotis' mission is to help millions of people all over the world to live for a longer time, in good health.
TypePublic
Founded2014
HQPerigny, FR
Websitevalbiotis.com

Latest Updates

Employees (est.) (Feb 2021)36
Share Price (Apr 2021)€7.8(+2%)
Cybersecurity ratingBMore

Key People/Management at Valbiotis

Laurent Levy

Laurent Levy

Chairman of the Supervisory Board
Sébastien Peltier

Sébastien Peltier

CEO & Chairman of the Board of Directors
Jocelyn Pineau

Jocelyn Pineau

CFO. Member of the Board of Directors
Jean Zetlaoui

Jean Zetlaoui

Medical Affairs and Clinical Development Consultant. Member of the Supervisory Board
Pascal Sirvent

Pascal Sirvent

CSO & Member of the Board of Directors
Agnès Tixier

Agnès Tixier

Executive Director, Crédit Mutuel, Equity SCR. Member of the Supervisory Board
Show more

Valbiotis Office Locations

Valbiotis has an office in Perigny
Perigny, FR (HQ)
Zone Industrielle des 4 Chevaliers, Bâtiment 12F, Rue Paul Vatine
Show all (1)

Valbiotis Financials and Metrics

Valbiotis Revenue

Market capitalization (9-Apr-2021)

60.2m

Closing stock price (9-Apr-2021)

7.8
Valbiotis's current market capitalization is €60.2 m.
Show all financial metrics

Valbiotis Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Valbiotis Online and Social Media Presence

Embed Graph

Valbiotis Blogs

As part of a global partnership with Nestlé Health Science, VALBIOTIS initiates the pivotal late stage development phase of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits in people with prediabetes

The article As part of a global partnership with Nestlé Health Science, VALBIOTIS initiates the pivotal late stage development phase of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits in people with prediabetes first appeared on Valbiotis.

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits on prediabetics

The article VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits on prediabetics first appeared on Valbiotis.

VALBIOTIS announces the success of its capital increase with maintenance of the DPS for an amount of 7.2 million euros (in French)

The article VALBIOTIS announces the success of its capital increase with maintenance of the DPS for an amount of 7.2 million euros (in French) first appeared on Valbiotis.

VALBIOTIS presents positive results from a study on TOTUM-63, active substance of VALEDIA®, at EASD 2019

The article VALBIOTIS presents positive results from a study on TOTUM-63, active substance of VALEDIA®, at EASD 2019 first appeared on Valbiotis.

Additional positive results from the Phase IIA clinical study on VALEDIA® in lipid metabolism and arterial hypertension

The article Additional positive results from the Phase IIA clinical study on VALEDIA® in lipid metabolism and arterial hypertension first appeared on Valbiotis.

Provision of the Registration Document (R 19-030) and Statement of cash position as of June 30, 2019 (in French)

The article Provision of the Registration Document (R 19-030) and Statement of cash position as of June 30, 2019 (in French) first appeared on Valbiotis.
Show more

Valbiotis Frequently Asked Questions

  • When was Valbiotis founded?

    Valbiotis was founded in 2014.

  • Who are Valbiotis key executives?

    Valbiotis's key executives are Laurent Levy, Sébastien Peltier and Jocelyn Pineau.

  • How many employees does Valbiotis have?

    Valbiotis has 36 employees.

  • Who are Valbiotis competitors?

    Competitors of Valbiotis include NovaVision, Foresight and Alseres Pharmaceuticals.

  • Where is Valbiotis headquarters?

    Valbiotis headquarters is located at Zone Industrielle des 4 Chevaliers, Bâtiment 12F, Rue Paul Vatine, Perigny.

  • Where are Valbiotis offices?

    Valbiotis has an office in Perigny.

  • How many offices does Valbiotis have?

    Valbiotis has 1 office.